Toggle menu

Relax 2 Trial

Start date:
June 2014
End date:
January 2016 (Close to recruitment)
Co-ordinated by:
Novartis
Main trial site:
RIE

A multicenter, randomised, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients (CRLXA).

Aim

To demonstrate that serelaxin is superior to placebo in reducing cardiovascular death in acute heart failure patients during a follow-up period of 180 days.

Trial Design

A randomised, double blind, placebo-controlled trial.

Chief Investigator

Metra Marco and Teerlink John for the RLX030A2301

Local PI

Dr Alasdair Gray

Research Team

Dr Martin Denvir – Co PI
Dr James Dear – Co PI
Dr Kristin Haga – Investigator
Dr Alastair Moss – Investigator
Polly Black – Research Nurse
Kirsty Simpson – Research Nurse
Rachel O’Brien – Research Nurse
Julia Grahamslaw – Research Nurse

Eligibility criteria (summary of )

Patients who are admitted to hospital with acute heart failure, who have received IV diuretics and have a degree of impaired renal function.

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Julia Grahamslaw

Lead Research Nurse

Kirsty Simpson

Senior Research Nurse

Rachel O'Brien

Lead Research Nurse

Polly Black

Senior Research Nurse

Emma Ward

Research Administrator

Related news

Research –A patient’s Perspective

Research –A patient’s Perspective

26 May 2015 | Polly Black

Meet Hilda. Hilda is 91 and has heart failure. In February 2015 participated in the RELAX 2 study and she kindly shared her experience with us.

Read more

More EMERGE Trials

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

Assisting in identifying patients with Humeral shaft fractures in the ED by screening.

Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.

Read more

HU-FIX Trial

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)